Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Remdesivir

If you want to know more about the Remdesivir, the following articles will give you some help. These news is the latest market situation, trend in development, or related tips of the Remdesivir industry. More news about Remdesivir, are being released. Follow us / contact us for more Remdesivir information!
  • Drug Patent & Exclusivity Expiration Report - Week of Jan 20 2024

    2025-01-20

    This week, there are 7 drugs in the patent and exclusivity list. They are: - CUMBERLAND PHARMACEUTICALS INC's SANCUSO, containing active ingredient GRANISETRON - AZURITY PHARMACEUTICALS INC's HORIZANT, containing active ingredient GABAPENTIN ENACARBIL - GILEAD SCIENCES INC's VEKLURY, containing active ingredient REMDESIVIR - ASTRAZENECA AB's BYDUREON BCISE, containing active ingredient EXENATIDE SYNTHETIC - EPIZYME INC's TAZVERIK, containing active ingredient TAZEMETOSTAT HYDROBROMIDE - EVOFEM INC's SOLOSEC, containing active ingredient SECNIDAZOLE - ADVANCED ACCELERATOR APPLICATIONS USA INC's LUTATHERA, containing active ingredient LUTETIUM LU 177 DOTATATE Read More